Immunic Therapeutics‘ experimental oral therapy vidofludimus calcium can target key mechanisms underlying disease progression in multiple sclerosis (MS), including acute and chronic inflammation, as well as Epstein-Barr virus (EBV) reactivation, according to new trial data. The Phase 2 CALLIPER trial (NCT05054140)Â investigated vidofludimus calcium against a…
Discussion
Like many of my peers in the military, I developed the ability to fall asleep in any position or place and at any time that I wasn’t actively engaged in something. On one occasion, during a particularly loud and turbulent flight, I managed to stay awake just long enough to…
People with multiple sclerosis (MS) who engage in more physical activity tend to have less severe physical and cognitive disability, a study demonstrated. While past exercise levels showed no correlation with later disease onset or slower disability accumulation, current exercise habits were significantly associated with physical disability in MS…
Discussion
Pain and I are well acquainted. I would not go so far as to say we are friends, but we do see each other every day. It isn’t always first thing in the morning; sometimes it’s midafternoon, right after I think to myself, “Wow, pain hasn’t shown up at my…
Bazedoxifene, a medication that alters the activity of the sex hormone estrogen, was safe and well-tolerated but did not promote myelin repair in women with multiple sclerosis (MS) in a Phase 2 clinical trial. The findings come from the ReWRAP study (NCT04002934) and were presented last week at…
Get regular updates to your inbox.
